We can all but dream.........
The Bakers have had failures,Tranzyme comes to mind.
Don't remind me lol. Biggest black eye in my portfolio last year.
This xoma run is different. Unlike the last cc debacle, the last two days have been almost straight up. No significant pullbacks means a big buyer is grabbing every last share, no retail effect.
Way too obvious leak.
Cheap pipeline at double the price.... think we get a buyer after the upcoming announcements due by 10/31.
Sentiment: Strong Buy
Xoma's monoclonal platform would be an extremely attractive addition to big pharma.